Il endometrial cancer it is a malignant tumor of the uterus, represents the fourth most common cause of cancer in females and occurs after menopause in 90% of cases with maximum incidence between the ages of 50 and 70. «In 9 out of ten diagnoses it is identified at an early stage, because it manifests itself with abnormal bleedingand for cases of advanced or recurrent cancer today a new drug has been shown to significantly reduce the risk of disease progression and death” he explains Giorgio ValabregaDirector of the SCDU Oncology Hospital of the Mauritian Order of Turin.
Endometrial cancer: dostarlimab and chemotherapy effective in advanced disease
The data presented at the annual meeting of the American Society of Gynecological Oncology, which recently took place in San Diego, have in fact demonstrated that the drug gotlimab in association with chemotherapy it reduces the risk of death by an average of 30% and in some cases the risk reduction reaches up to 70%.
«At the American congress, the first clinical study capable of showing a statistically and clinically significant improvement in overall survival for an immuno-oncology therapy in combination with chemotherapy in the overall population of patients with advanced primary disease or recurrent endometrial cancer was presented» , he confirms Sunday LorussoHead of Medical Gynecology Oncology Humanitas San Pio
«This study changes clinical practice for all patients. Women with advanced or recurrent endometrial cancer, if treated with chemotherapy and immunotherapy at the time of recurrence, experience a survival benefit, with a 30% reduction in the risk of death. Not only that: in women who have a particular type of endometrial cancer, the one with microsatellite instability, the reduction in the risk of death reaches 70%”.